BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27835596)

  • 21. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
    Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
    Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
    Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells.
    Kreppel M; Aryee DN; Schaefer KL; Amann G; Kofler R; Poremba C; Kovar H
    Oncogene; 2006 May; 25(19):2795-800. PubMed ID: 16314831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EHD1-dependent traffic of IGF-1 receptor to the cell surface is essential for Ewing sarcoma tumorigenesis and metastasis.
    Chakraborty S; Bhat AM; Mushtaq I; Luan H; Kalluchi A; Mirza S; Storck MD; Chaturvedi N; Lopez-Guerrero JA; Llombart-Bosch A; Machado I; Scotlandi K; Meza JL; Ghosal G; Coulter DW; Jordan Rowley M; Band V; Mohapatra BC; Band H
    Commun Biol; 2023 Jul; 6(1):758. PubMed ID: 37474760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
    Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
    Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Tumor Vascular CD99 Inhibits Tumor Growth.
    Huijbers EJM; van der Werf IM; Faber LD; Sialino LD; van der Laan P; Holland HA; Cimpean AM; Thijssen VLJL; van Beijnum JR; Griffioen AW
    Front Immunol; 2019; 10():651. PubMed ID: 31001265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapies in Ewing's sarcoma.
    Scotlandi K
    Adv Exp Med Biol; 2006; 587():13-22. PubMed ID: 17163152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
    Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
    Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
    Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
    PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Application of the in situ hybridization with EWS dual-color break-apart fluorescence probe and anti-CD99 and anti-FLI-1 antibodies in the diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor].
    Liu BY; Yang Y; DU J; Zhang Y; Wang H; Zheng J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):358-62. PubMed ID: 18677380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EWS-FLI-1 creates a cell surface microenvironment conducive to IGF signaling by inducing pappalysin-1.
    Jayabal P; Houghton PJ; Shiio Y
    Genes Cancer; 2017 Nov; 8(11-12):762-770. PubMed ID: 29321818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.
    Santoro M; Menegaz BA; Lamhamedi-Cherradi SE; Molina ER; Wu D; Priebe W; Ludwig JA; Mikos AG
    Tissue Eng Part A; 2017 Jan; 23(1-2):80-89. PubMed ID: 27923328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models.
    Guiho R; Biteau K; Grisendi G; Taurelle J; Chatelais M; Gantier M; Heymann D; Dominici M; Redini F
    Int J Cancer; 2016 Dec; 139(12):2802-2811. PubMed ID: 27558972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.
    Santoro M; Lamhamedi-Cherradi SE; Menegaz BA; Ludwig JA; Mikos AG
    Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10304-9. PubMed ID: 26240353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.